- Home
- MYFW vs CRVS Comparison
MYFW vs CRVS Comparison
Compare MYFW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYFW
- CRVS
- Stock Information
- Founded
- MYFW 2002
- CRVS 2014
- Country
- MYFW United States
- CRVS United States
- Employees
- MYFW N/A
- CRVS N/A
- Industry
- MYFW Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- MYFW Finance
- CRVS Health Care
- Exchange
- MYFW Nasdaq
- CRVS Nasdaq
- Market Cap
- MYFW 169.4M
- CRVS 161.4M
- IPO Year
- MYFW 2018
- CRVS 2016
- Fundamental
- Price
- MYFW $19.51
- CRVS $5.91
- Analyst Decision
- MYFW Buy
- CRVS Buy
- Analyst Count
- MYFW 3
- CRVS 4
- Target Price
- MYFW $20.67
- CRVS $10.83
- AVG Volume (30 Days)
- MYFW 21.2K
- CRVS 470.3K
- Earning Date
- MYFW 10-17-2024
- CRVS 11-05-2024
- Dividend Yield
- MYFW N/A
- CRVS N/A
- EPS Growth
- MYFW N/A
- CRVS N/A
- EPS
- MYFW 0.36
- CRVS N/A
- Revenue
- MYFW $80,146,000.00
- CRVS N/A
- Revenue This Year
- MYFW N/A
- CRVS N/A
- Revenue Next Year
- MYFW $11.04
- CRVS N/A
- P/E Ratio
- MYFW $55.41
- CRVS N/A
- Revenue Growth
- MYFW N/A
- CRVS N/A
- 52 Week Low
- MYFW $12.84
- CRVS $1.05
- 52 Week High
- MYFW $21.15
- CRVS $6.15
- Technical
- Relative Strength Index (RSI)
- MYFW 57.61
- CRVS 75.58
- Support Level
- MYFW $19.58
- CRVS $5.25
- Resistance Level
- MYFW $20.42
- CRVS $4.75
- Average True Range (ATR)
- MYFW 0.59
- CRVS 0.45
- MACD
- MYFW 0.05
- CRVS 0.10
- Stochastic Oscillator
- MYFW 59.73
- CRVS 89.33
About MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).